Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04201873
Title Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

glioblastoma

Therapies

DC tumor cell lysate vaccine + Poly ICLC

DC tumor cell lysate vaccine + Pembrolizumab + Poly ICLC

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.